Related Experiment Video
Updated: May 11, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Expression of topoisomerase II-α in triple negative breast cancer
Ivana Mrklić1, Zenon Pogorelić, Vesna Ćapkun
1Departments of *Pathology, Forensic Medicine and Cytology †Pediatric Surgery ‡Nuclear Medicine, Split University Hospital Centre, School of Medicine, University of Split, Split, Croatia.
Abstract:
Triple negative breast cancer (TNBC)-defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 negativity is a group with poor prognosis, due to aggressive tumor biology and lack of targeted therapy. Topoisomerase II-α (topoIIα) protein is one of the intracellular targets for anthracycline-based therapy, and high levels of topoIIα expression are recently observed in TNBC. The study included 83 patients who underwent surgery between January 2003 and December 2009. Paraffin blocks were stained immunohistochemically with CK5/6, CK14, EGFR, Ki-67, and topoIIα. Basal-like (BL) immunophenotype was defined by positivity for ≥1 basal cell markers: CK5/6, CK14, or EGFR. Of 83 TNBC, 66.26% were of the BL immunophenotype, which was significantly associated with higher mitotic count (P=0.023), BL morphology (P=0.005), higher histologic grade (P=0.022), and higher proliferation rate assessed by Ki-67 (P<0.001). TopoIIα expression was significantly correlated with invasive ductal carcinoma NOS (P=0.010), higher mitotic count (P=0.001), higher histologic grade (P=0.007), and higher Ki-67 (P<0.001). In conclusion, due to lack of expression of ER, PR, and human epidermal growth factor receptor 2 receptor in TNBC, specific targeted therapies are not effective, and chemotherapy is currently the only modality of available systemic therapy. Due to expression of topoIIα, anthracyclines may be effective in treatment of TNBC.
Insights
Triple negative breast cancer (TNBC) lacks targeted therapies. High topoisomerase II-alpha (topoIIα) expression in TNBC suggests anthracycline chemotherapy may be effective for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Triple-negative breast cancer (TNBC) presents a poor prognosis due to aggressive tumor biology and limited targeted therapy options.
- Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negativity defines TNBC.
- Topoisomerase II-alpha (topoIIα) is an intracellular target for anthracycline chemotherapy, with elevated expression noted in TNBC.
Purpose of the Study:
- To investigate the prevalence of basal-like (BL) immunophenotype in TNBC.
- To assess the correlation between BL immunophenotype, proliferation markers, and tumor characteristics.
- To evaluate the expression of topoIIα in TNBC and its potential therapeutic implications.
Main Methods:
- Immunohistochemical staining was performed on 83 TNBC patient samples (surgery dates: Jan 2003 - Dec 2009).
- Markers analyzed included CK5/6, CK14, EGFR, Ki-67, and topoIIα.
- Basal-like (BL) immunophenotype was defined by positivity for CK5/6, CK14, or EGFR.
Main Results:
- 66.26% of TNBC cases exhibited the BL immunophenotype, significantly associated with higher mitotic count, BL morphology, histologic grade, and Ki-67 proliferation rate.
- TopoIIα expression showed significant correlation with invasive ductal carcinoma NOS, higher mitotic count, histologic grade, and Ki-67.
- A strong association was found between topoIIα expression and high proliferation rates (Ki-67).
Conclusions:
- TNBC's lack of ER, PR, and HER2 expression limits targeted therapies, making chemotherapy the primary systemic treatment.
- The observed topoIIα expression in TNBC suggests potential efficacy of anthracycline-based chemotherapy.
- Targeting topoIIα could represent a viable therapeutic strategy for TNBC patients.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...

